CSF1R-inhibitor resistant model for CNS-wide microglia replacement strategies

Recent advances in cell-based therapies have demonstrated therapeutic safety and efficacy for a variety of diseases. However, significant challenges remain in their development for the treatment of neurological disorders. Preclinical studies have explored microglial replacement strategies utilizing bone marrow transplantation and CSF1R-inhibitor (CSF1Ri) treatment. However, these approaches often require highly invasive strategies and result in engrafted cells that remain transcriptionally and functionally distinct from microglia. To assess less invasive microglia replacement strategies capable of preserving microglial ontogeny, we developed a Csf1r-G793A knockin mouse. We found G793A mice develop typical microglial densities and peripheral hematopoietic populations which exhibit broad CSF1Ri resistance enabling widespread microglia replacement following direct intraparenchymal injection or bone marrow transplantation. Furthermore, we demonstrate that widespread microglia replacement can be achieved via less invasive intracisternal delivery of CSF1Ri-resistant murine and iPSC-derived human microglia. Together with the accompanying study by Lombroso and colleagues, our findings demonstrate that G793A mice provide a robust and broadly applicable source of engraftable donor microglia and peripheral macrophages for the preclinical investigation of microglia replacement strategies. Overall design: WT or Csf1R-G793A (C57BL/6J) mice were fed control, PLX3397 (290mg/kg), or PLX5622 (1200mg/kg) for 14 days to examine the effects of Csf1R-G793A mutation (WT-control vs G793A-control), PLX3397 (WT-control vs WT-3397), and PLX5622 (WT-control vs WT-5622) on the brain transcriptome and whether CSF1R-inhibitor effects were prevented by Csf1R-G793A (WT-control vs G793A-3397) (WT-control vs G793A-5622). WT-control, n=3. G793A-control, n=4. WT-3397, n=4. G793A-3397, n=4. WT-5622, n=4. WT-5622, n=4